Market Place
Sourcing Support
Recordati Rare Diseases, Pedea 5 mg/ml solution for injection, EL(22)A/45
27 Oct 2022 //
GOVUK
Recordati Announce Publication of Outcomes From PIII LINC 3 Study of Isturisa
31 Aug 2022 //
BUSINESSWIRE
Phase III LINC 3 Study Says ISTURISA Shows Improvement in Cushing’s Disease
13 May 2022 //
BUSINESSWIRE
Recordati Rare Diseases Announces William Ludlam As New Chief Medical Officer
25 Aug 2021 //
BUSINESSWIRE
Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study
23 Mar 2021 //
BUSINESSWIRE
Recordati: Positive Results From the Phase III LINC-4 Study at the Endocrine
23 Mar 2021 //
BUSINESSWIRE
Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study
22 Mar 2021 //
BUSINESSWIRE
Recordati Rare Diseases Announces Availability of CYSTADROPS in the U.S.
15 Sep 2020 //
BIOSPACE
U.S. FDA Approves CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%
25 Aug 2020 //
PRNEWSWIRE
CVC revs up rare disease ambitions with $3.5B Recordati buy
05 Jul 2018 //
FIERCE PHARMA
Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection)
05 Jul 2017 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.